Lpath, Inc. Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
5/30/2013 9:18:04 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 30, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that the Company has been issued a key patent supporting its iSONEP program.
Help employers find you! Check out all the jobs and post your resume.
comments powered by